Identification of estrogen receptor down-regulators for endocrine resistant breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identification of estrogen receptor down-regulators for endocrine resistant breast cancer

Published:2022-11 Issue: Volume:224 Page:106162
ISSN:0960-0760
Container-title:The Journal of Steroid Biochemistry and Molecular Biology
language:en
Short-container-title:The Journal of Steroid Biochemistry and Molecular Biology

Author:

Li Yaxin,Orahoske Cody M.,Urmetz Shannon M.,Zhang Wenjing,Huang Yanmin,Gan Chunfang,Su Bin

Funder

National Natural Science Foundation of China

Cleveland State University

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Endocrinology,Molecular Biology,Molecular Medicine,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference21 articles.

1. The natural history of hormone receptor-positive breast cancer;Elgene Lim;Oncology,2012

2. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer;Robertson;Eur. J. Cancer,2021

3. Endocrine resistance in breast cancer–an overview and update;Clarke;Mol. Cell. Endocrinol.,2015

4. Palbociclib and letrozole in advanced breast cancer;Finn;N. Engl. J. Med.,2016

5. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review;Lambert;Breast Cancer Res. Treat.,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comparative study of Bazedoxifene, Exemestane, Fulvestrant, Raloxifene, Tryprostatin A, and Vorinostat compounds as potential inhibitors against breast cancer through molecular docking, and molecular dynamics simulation;Chinese Journal of Analytical Chemistry;2023-10

2. Elacestrant: a new FDA-approved SERD for the treatment of breast cancer;Medical Oncology;2023-05-16

3. The crosstalk between ubiquitination and endocrine therapy;Journal of Molecular Medicine;2023-03-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3